DE60008001D1 - Lokale verabreichung von 17-beta estradiol zur verbesserung der vaskularen endothelialen funktion nach gefässverletzungen - Google Patents

Lokale verabreichung von 17-beta estradiol zur verbesserung der vaskularen endothelialen funktion nach gefässverletzungen

Info

Publication number
DE60008001D1
DE60008001D1 DE60008001T DE60008001T DE60008001D1 DE 60008001 D1 DE60008001 D1 DE 60008001D1 DE 60008001 T DE60008001 T DE 60008001T DE 60008001 T DE60008001 T DE 60008001T DE 60008001 D1 DE60008001 D1 DE 60008001D1
Authority
DE
Germany
Prior art keywords
vascular
local administration
beta estradiol
endothelial function
injuries
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60008001T
Other languages
English (en)
Other versions
DE60008001T2 (de
Inventor
Baskaran Chandrasekar
Jean-Francois Tanguay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut de Cardiologie de Montreal
Original Assignee
Institut de Cardiologie de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2282982 external-priority patent/CA2282982A1/en
Priority claimed from CA002300246A external-priority patent/CA2300246A1/en
Application filed by Institut de Cardiologie de Montreal filed Critical Institut de Cardiologie de Montreal
Publication of DE60008001D1 publication Critical patent/DE60008001D1/de
Application granted granted Critical
Publication of DE60008001T2 publication Critical patent/DE60008001T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60008001T 1999-09-21 2000-09-21 Lokale verabreichung von 17-beta estradiol zur verbesserung der vaskularen endothelialen funktion nach gefässverletzungen Expired - Lifetime DE60008001T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA 2282982 CA2282982A1 (en) 1999-09-21 1999-09-21 Local delivery of 17 - beta estradiol during balloon angioplasty for preventing restenosis
CA2282982 1999-09-21
CA002300246A CA2300246A1 (en) 2000-03-09 2000-03-09 Local delivery of 17-beta estradiol decreases neointimal hyperplasia following coronary angioplasty in porcine model
CA2300246 2000-03-09
PCT/CA2000/001132 WO2001021157A2 (en) 1999-09-21 2000-09-21 Local delivery of 17-beta estradiol for preventing vascular intima hyperplasia and for improving vascular endothelium function after vascular injury

Publications (2)

Publication Number Publication Date
DE60008001D1 true DE60008001D1 (de) 2004-03-04
DE60008001T2 DE60008001T2 (de) 2004-09-02

Family

ID=25681212

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60008001T Expired - Lifetime DE60008001T2 (de) 1999-09-21 2000-09-21 Lokale verabreichung von 17-beta estradiol zur verbesserung der vaskularen endothelialen funktion nach gefässverletzungen

Country Status (11)

Country Link
US (1) US20070141109A1 (de)
EP (1) EP1214077B1 (de)
JP (1) JP3820150B2 (de)
AT (1) ATE258441T1 (de)
AU (1) AU766208B2 (de)
DE (1) DE60008001T2 (de)
DK (1) DK1214077T3 (de)
ES (1) ES2215069T3 (de)
MX (1) MXPA02003009A (de)
PT (1) PT1214077E (de)
WO (1) WO2001021157A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471979B2 (en) * 1999-12-29 2002-10-29 Estrogen Vascular Technology, Llc Apparatus and method for delivering compounds to a living organism
DE10107795B4 (de) * 2001-02-13 2014-05-15 Berlex Ag Gefäßstütze mit einem Grundkörper, Verfahren zur Herstellung der Gefäßstütze, Vorrichtung zur Beschichtung der Gefäßstütze
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
US10441747B2 (en) 2002-01-22 2019-10-15 Mercator Medsystems, Inc. Methods and systems for inhibiting vascular inflammation
US7744584B2 (en) 2002-01-22 2010-06-29 Mercator Medsystems, Inc. Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation
US7361368B2 (en) 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
WO2004024206A1 (en) * 2002-09-12 2004-03-25 Estrogen Vascular Technology, Llc Apparatus and method for delivering compounds to a living organism
US8383158B2 (en) 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8038991B1 (en) 2003-04-15 2011-10-18 Abbott Cardiovascular Systems Inc. High-viscosity hyaluronic acid compositions to treat myocardial conditions
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US7732190B2 (en) 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
CA2711818A1 (en) * 2007-09-20 2009-03-26 Estracure Inc. Method of reducing the effects of cytostatic drugs on bone marrow derived cells, and methods of screening
US20090274738A1 (en) * 2008-05-01 2009-11-05 Jean-Francois Tanguay Implantable devices for promoting reendothelialization and methods of use thereof
US20100233266A1 (en) * 2009-03-13 2010-09-16 Cleek Robert L Articles and methods of treating vascular conditions
WO2017004518A1 (en) * 2015-07-02 2017-01-05 The Regents Of The University Of California Site-targeted nano-liposomal nitroglycerin therapeutics
CA3035774A1 (en) 2016-09-22 2018-03-29 Mercator Medsystems, Inc. Treatment of restenosis using temsirolimus
EP3629774A4 (de) 2017-05-26 2021-03-03 Mercator Medsystems, Inc. Kombinationstherapie zur behandlung von restenose
EP3765122A4 (de) 2018-03-14 2021-12-15 Mercator Medsystems, Inc. Medizinisches instrument und medizinisches verfahren zur lokalisierten wirkstofffreisetzung
EP3747992A1 (de) * 2019-06-04 2020-12-09 Medizinische Hochschule Hannover Zusammensetzungen und verfahren zur integration von zellen in das epithel

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5512557A (en) * 1993-10-07 1996-04-30 National Heart And Lung Institute Coronary heart disease treated with 17βoestradiol
US5376652A (en) * 1993-11-30 1994-12-27 New York University Medical Center Administration of a 27-hydroxycholesterol or related compound or sterol-27-hydroxylase stimulant to prevent restenosis following vascular endothelial injury
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
AU716005B2 (en) * 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
WO1998056312A1 (en) * 1997-06-13 1998-12-17 Scimed Life Systems, Inc. Stents having multiple layers of biodegradable polymeric composition
US5866561A (en) * 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis
WO2000010552A2 (en) * 1998-08-24 2000-03-02 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury
WO2000012147A1 (en) * 1998-09-02 2000-03-09 Scimed Life Systems, Inc. Drug delivery device for stent

Also Published As

Publication number Publication date
US20070141109A1 (en) 2007-06-21
AU766208B2 (en) 2003-10-09
JP3820150B2 (ja) 2006-09-13
WO2001021157A3 (en) 2001-12-13
AU7501900A (en) 2001-04-24
ES2215069T3 (es) 2004-10-01
WO2001021157A2 (en) 2001-03-29
EP1214077B1 (de) 2004-01-28
MXPA02003009A (es) 2005-02-17
ATE258441T1 (de) 2004-02-15
DE60008001T2 (de) 2004-09-02
EP1214077A2 (de) 2002-06-19
DK1214077T3 (da) 2004-06-07
PT1214077E (pt) 2004-05-31
JP2003509456A (ja) 2003-03-11

Similar Documents

Publication Publication Date Title
DE60008001D1 (de) Lokale verabreichung von 17-beta estradiol zur verbesserung der vaskularen endothelialen funktion nach gefässverletzungen
EP1231864A4 (de) Am gewebe befestigbarer medikamentenverabreichungskatheter und methode zu deren anwendung
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
PL321363A1 (en) Preparation of controllable drug release within a patient's body in particular for slightly soluble nasic drugs
PL334656A1 (en) Dosage forms and methods of achieving betterement in cases of erection disorderamong male patients
AU5325000A (en) Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
NZ514464A (en) Apomorphine and sildenafil composition
IL136839A0 (en) Pharmaceutical compositions comprising cannabidiol derivatives
IL144730A (en) Use of statin drug in the preparation of a medicament and as a medicament for the treatment of diabetic neuropathy
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
HK1049444A1 (en) Transdermal therapeutic system for parkingson's disease inducing high plasma levels of rotigotine
WO2001028542A3 (en) Combination therapy including camptothecin
NZ514558A (en) Viral treatment
JP2004537500A5 (de)
IL147876A0 (en) Use of agonists of gabab receptors and pharmaceutically acceptable derivatives thereof, in the therapy of maintaining nicotine abstinence-dependent patients
PT1027053E (pt) Metodo de prevencao de nefrotoxicidade provocada por ciclosporinas e tacrolimus
HK1045458A1 (en) Ophthalmic histtamine compositions and uses thereof.
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
MD1875F1 (en) Method of treatment of the acute viral hepatitis B
EA200200914A1 (ru) Система контроля дозирования для однократного ежедневного приема назначенного ципрофлоксацина
IL144380A0 (en) Method of enhancing needleless transdermal powdered drug delivery
WO2000048582A3 (de) Pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der drogenabhängigkeit
AU2002253785A1 (en) Catheter and implants for the delivery of therapeutic agents to tissues
GB9930077D0 (en) Medicaments
James San Francisco area: testosterone replacement study, injection vs. patch

Legal Events

Date Code Title Description
8364 No opposition during term of opposition